What is the recommended dosage of Moisol (timolol) eye drops for treating glaucoma and ocular hypertension?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 3, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Timolol (Moisol) Eye Drops Dosage for Glaucoma and Ocular Hypertension

Start with one drop of timolol 0.25% in the affected eye(s) twice daily, and if the response is inadequate after 4 weeks, increase to timolol 0.5% twice daily. 1

Standard Dosing Protocol

  • Initial dose: One drop of timolol 0.25% solution in the affected eye(s) twice daily 1
  • Dose escalation: If clinical response is inadequate, increase to one drop of timolol 0.5% solution twice daily 1
  • Evaluation timing: Assess intraocular pressure (IOP) after approximately 4 weeks of treatment, as the pressure-lowering response may require several weeks to stabilize 1

Dosing Optimization

  • Once-daily option: If IOP is maintained at satisfactory levels on twice-daily dosing, the schedule may be changed to one drop once daily 1
  • Timing consideration: Because of diurnal IOP variations, the adequacy of once-daily dosing is best determined by measuring IOP at different times during the day 1
  • Maximum dose: Dosages above one drop of timolol 0.5% twice daily generally have not been shown to produce further IOP reduction 1

When Monotherapy Is Insufficient

  • Combination therapy: If IOP remains unsatisfactory on maximum timolol dosing, add concomitant therapy with other IOP-lowering agents 1
  • Avoid dual beta-blockers: Do not use two topical beta-adrenergic blocking agents simultaneously 1
  • Alternative first-line agents: Prostaglandin analogs are the most frequently prescribed initial therapy for glaucoma because they are most efficacious, well-tolerated, and require only once-daily dosing 2, 3

Treatment Goals and Monitoring

  • Target IOP: Aim for approximately 20% lower than baseline mean IOP measurements 2, 4
  • Regular assessment: Evaluate IOP at each visit and adjust target pressure based on optic nerve structure and visual field stability 2
  • Long-term efficacy: Timolol 0.5% twice daily produces mean IOP reductions of 5.6-6.6 mm Hg at trough and similar reductions at peak 5

Administration Technique

  • Reduce systemic absorption: Educate patients about eyelid closure or nasolacrimal duct occlusion when applying drops to minimize systemic side effects 2
  • Multiple drop regimens: Wait at least 5 minutes between different eye drop medications 2
  • Adherence support: Link eye-drop administration to daily activities and provide repeated instruction on proper technique 2

Important Caveats

  • Cardiovascular effects: Timolol can cause decreases in heart rate (mean reduction of 4-5 bpm), though blood pressure changes are typically not significant 5
  • Pregnancy category: Timolol is FDA Pregnancy Category C; beta-blockers tend to be used during pregnancy due to long-term experience, but careful risk-benefit assessment is required 2
  • Adherence challenges: Nearly 45% of patients take fewer than 75% of prescribed doses even with instruction; simplified regimens and counseling improve adherence 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Pregabalin Use in Open-Angle Glaucoma

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Antidepressants in Patients with Glaucoma

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.